Synthon and MIVAC Development enter into exclusive research collaboration and commercial licensing agreement in multiple sclerosis
The collaboration will combine Synthon’s expertise in the pharmaceutical arena and business acumen with MIVAC Development’s tolerance-inducing fusion protein technology.
Under the collaboration, Synthon and MIVAC Development will create multiple new therapeutic candidates, research and screen these to identify novel lead compounds which Synthon will develop further into the clinic and bring onto the market.
The result of this collaboration could be a new treatment paradigm for multiple sclerosis patients offering superior efficacy with greater ease of use and improved tolerability.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.